Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 4, 2026Reported purchase · Form 4Albert Luderer, Interim Chief Executive · $4.8KOpen the filing ↗
- Aug 21, 2026Reported purchase · Form 4Albert Luderer, Interim Chief Executive · $4.9KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record56016 flagged findings
Reported transactions (Form 4)80since May 12, 2023 · and 17 other holdings
Corporate events (8-K)30since Apr 14, 2023
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-08-10share offering or dilution eventfreshOpen filing ↗“…June 30, 2026 2025 2026 2025 Other interest expense ( 70 ) ( 73 ) ( 142 ) ( 158 ) Changes in estimated fair value on convertible…”
+1 more passage from the same document
- “…Other Income (Expense), Net The following is a summary of the charges included within other income (expense), net on the unaudited…”
- 2026-08-10reverse splitfreshOpen filing ↗“…absence of heterozygosity across the genome in one consolidated view. The Company also offers nucleic acid extraction and…”
+1 more passage from the same document
- “…its wholly-owned subsidiary, Lineagen Inc. (doing business as Bionano Laboratories), the Company also provides OGM-based diagnostic…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
Reverse splits in 5 years
2 reverse splits in 5 years (1:10 on Aug 7, 2023, 1:60 on Jan 27, 2025) · 1:600 cumulative
The other times: of 247 securities that repeated a reverse split in 5 years, a year later the median was worth 0.10× the price on the day of the split; 189 lost more than half and 21 rose (243 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 560)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 14, 268-K ↗Current report · Communication to the market
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · CVI Investments, Inc. · 9.9% · event on Jun 30, 26 · amendment
- Aug 10, 2610-Q ↗Quarterly report
- Aug 10, 268-K ↗Current report · Results
- Aug 5, 26Form 4 ↗Insider transaction
- Aug 5, 26Form 3 ↗Insider transaction
- Aug 5, 26Form 4 ↗Insider transaction
- Aug 5, 26Form 3 ↗Insider transaction
- Aug 5, 26Form 4 ↗Insider transaction
- Aug 5, 26Form 3 ↗Insider transaction
- Aug 5, 26Form 4 ↗Insider transaction
- Jun 24, 268-K ↗Current report · Other events
- Jun 5, 268-K ↗Current report · A senior executive left or was appointed
- May 28, 268-K ↗Current report · Other events
560 filings on record, the oldest from Jun 8, 18.
Listing the 25 most recent filings of the 560 on record.
84217
- Jun 5, 26A senior executive left or was appointed8-K 5.02 ↗
- May 6, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 18, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jun 13, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 21, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Feb 10, 25A material agreement was terminated8-K 1.02 ↗
- Jan 6, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Jan 3, 25Sold unregistered shares+3 more in the same filing8-K 3.02 ↗
- Oct 31, 24Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Sep 9, 24Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
- Jul 18, 24Listing notice (8-K 3.01)8-K 3.01 ↗
- Jul 8, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
9 older filings not shown · The record reaches back to Nov 21, 18.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- May 8, 24Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Mar 5, 24Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Oct 11, 23Restructuring plan with committed costs+6 more in the same filing8-K 2.05 ↗
- Jun 2, 23Listing notice (8-K 3.01)8-K 3.01 ↗
- Apr 24, 20Listing notice (8-K 3.01)8-K 3.01 ↗
- Aug 22, 19Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
The full record holds 8 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Ayrton Capital LLC10.0%Sep 30, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- CVI Investments, Inc.9.9%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 4 earlier filings
- Lind Global Fund III LP9.3%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Lincoln Alternative Strategies LLC5.4%Sep 17, 25SCHEDULE 13G ↗
- Richard Abbe5.0%Sep 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
show 2 more holdershide
- Iroquois Capital Management, LLC5.0%Sep 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- Mitchell P. Kopin5.0%Sep 16, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Stock compensation, tax and giftsshow the 36 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Jun 3, 26Tax$35MARK OLDAKOWSKICHIEF OPERATING OFFICER↗
- Jun 3, 26Tax$31Alka ChaubeyCHIEF MEDICAL OFFICER↗
- Jun 3, 26Tax$31Jonathan V. DixonGENERAL COUNSEL↗
- Jun 3, 26Tax$9Mark AdamchakPrincipal Accounting Officer↗
- Feb 17, 26Tax$56R. Erik HolmlinPRESIDENT AND CEO↗
- Feb 17, 26Tax$22MARK OLDAKOWSKICHIEF OPERATING OFFICER↗
- Feb 17, 26Tax$20Alka ChaubeyCHIEF MEDICAL OFFICER↗
- Feb 17, 26Tax$7Jonathan V. DixonGENERAL COUNSEL↗
- Feb 17, 26Tax$3Mark AdamchakPrincipal Accounting Officer↗
- Sep 11, 25Tax$240MARK OLDAKOWSKIChief Operating Officer↗
- Sep 11, 25Tax$207Alka ChaubeyChief Medical Officer↗
- Jun 3, 25Tax$92Jonathan V. DixonGeneral Counsel↗
- Jun 3, 25Tax$277R. Erik HolmlinPresident and CEO↗
- Jun 3, 25Tax$89Alka ChaubeyChief Medical Officer↗
- Jun 3, 25Tax$26Mark AdamchakPrincipal Accounting Officer↗
- Jun 3, 25Tax$100MARK OLDAKOWSKIChief Operating Officer↗
- Mar 14, 25Tax$687R. Erik HolmlinPresident and CEO↗
- Feb 15, 25Tax$23Mark AdamchakPrincipal Accounting Officer↗
- Feb 15, 25Tax$103Alka ChaubeyChief Medical Officer↗
- Feb 15, 25Tax$292R. Erik HolmlinPresident and CEO↗
- Feb 15, 25Tax$34Jonathan V. DixonGeneral Counsel↗
- Feb 15, 25Tax$115MARK OLDAKOWSKIChief Operating Officer↗
- Sep 11, 24Tax$1KAlka ChaubeyChief Medical Officer↗
- Sep 11, 24Tax$2KMARK OLDAKOWSKIChief Operating Officer↗
- Jun 3, 24Compensationamount n/aAlka ChaubeyCHIEF MEDICAL OFFICER↗
- Jun 3, 24Compensationamount n/aJonathan V. DixonGENERAL COUNSEL↗
- Jun 3, 24Compensationamount n/aR. Erik HolmlinPRESIDENT AND CEO↗
- Jun 3, 24Compensationamount n/aGulsen KamaChief Financial Officer↗
- Jun 3, 24Compensationamount n/aMARK OLDAKOWSKICHIEF OPERATING OFFICER↗
- Feb 15, 24Tax$511Jonathan V. DixonGENERAL COUNSEL↗
- Feb 15, 24Tax$4KR. Erik HolmlinPRESIDENT AND CEO↗
- Feb 15, 24Tax$2KMARK OLDAKOWSKICHIEF OPERATING OFFICER↗
- Feb 15, 24Tax$1KAlka ChaubeyCHIEF MEDICAL OFFICER↗
- Sep 18, 23Compensationamount n/aAlka ChaubeyChief Medical Officer↗
- Sep 18, 23Compensationamount n/aMARK OLDAKOWSKIChief Operating Officer↗
- May 12, 23Tax$33KR. Erik HolmlinPresident and CEO↗
The full record holds 46 transactions and goes back to Feb 15, 23.
Its sector and its market
Bionano Genomics Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Bionano Genomics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Bionano Genomics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 560 documents on file, from Jun 8, 2018 to Sep 14, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.